Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Vertex Pharmaceuticals Inc (VRTX)  
$437.49 8.90 (2.08%) as of 4:30 Wed 5/15


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 260,040,000
Market Cap: 113.76(B)
Last Volume: 1,059,413 Avg Vol: 1,615,310
52 Week Range: $323.57 - $446.08
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     NASDAQ-100
    S&P 400 MIDCAP     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  543
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 45,457 125,099 237,443 597,852
Total Sell Value $19,193,323 $51,578,069 $92,174,963 $199,924,371
Total People Sold 8 11 14 18
Total Sell Transactions 19 38 60 128
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 3266
  Page 14 of 131  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Ambrose Kristen SVP & Chief Accounting Officer   •       –      –    2022-04-01 4 D $263.09 $36,043 D/D (137) 3,823     -
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2022-04-01 4 D $263.09 $353,593 D/D (1,344) 47,068     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2022-04-01 4 AS $261.42 $683,602 D/D (2,582) 43,620 10%     
   Mcglynn Margaret G Director   –       •      –    2022-03-31 4 AS $261.28 $1,311,346 D/D (5,000) 1,099 13%     
   Mcglynn Margaret G Director   –       •      –    2022-03-31 4 OE $127.54 $637,700 D/D 5,000 6,099     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2022-03-17 4 AS $250.13 $793,218 D/D (3,171) 46,202 15%     
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2022-03-17 4 AS $250.10 $708,572 D/D (2,833) 47,356 15%     
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2022-03-17 4 AS $250.06 $530,627 D/D (2,122) 48,412 15%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2022-02-25 4 AS $229.41 $1,748,990 D/D (7,572) 36,077 28%     
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2022-02-25 4 AS $228.88 $75,058 D/D (325) 50,189 28%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2022-02-24 4 D $227.86 $1,375,819 D/D (6,038) 43,649     -
   Arbuckle Stuart A EVP, COO   •       –      –    2022-02-24 4 D $227.86 $1,651,074 D/D (7,246) 65,066     -
   Leiden Jeffrey M Executive Chairman   •       •      –    2022-02-24 4 D $227.86 $2,766,448 D/D (12,141) 89,949     -
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2022-02-24 4 D $227.86 $590,157 D/D (2,590) 50,514     -
   Liu Joy SVP, General Counsel   •       –      –    2022-02-24 4 D $227.86 $354,094 D/D (1,554) 14,454     -
   Bozic Carmen EVP and CMO   •       –      –    2022-02-24 4 D $227.86 $283,002 D/D (1,242) 49,823     -
   Kewalramani Reshma CEO & President   •       •      –    2022-02-24 4 D $227.86 $1,651,074 D/D (7,246) 122,842     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2022-02-24 4 D $227.86 $498,786 D/D (2,189) 49,373     -
   Sachdev Amit EVP, Chief Patient Officer   •       –      –    2022-02-24 4 D $227.86 $1,678,872 D/D (7,368) 48,210     -
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2022-02-18 4 AS $229.52 $119,889 D/D (519) 53,104 23%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2022-02-18 4 AS $229.22 $995,949 D/D (4,312) 49,687 23%     
   Arbuckle Stuart A EVP, COO   •       –      –    2022-02-17 4 D $232.51 $959,336 D/D (4,126) 72,312     -
   Bozic Carmen EVP and CMO   •       –      –    2022-02-17 4 D $232.51 $799,602 D/D (3,439) 51,065     -
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2022-02-17 4 D $232.51 $956,546 D/D (4,114) 53,623     -
   Liu Joy SVP, General Counsel   •       –      –    2022-02-17 4 D $232.51 $165,547 D/D (712) 16,008     -
  3266 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 14 of 131
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us